Publikasi Scopus FKUI 2021 per tanggal 31 Juli 2021 (507 artikel)

Octaviana F., Yugo H.P., Safri A.Y., Indrawati L.A., Wiratman W., Ayuningtyas T., Hakim M.
26029958700;57222124227;57091699300;57205117182;57191920526;57222133312;57216861859;
Case series: COVID-19 in patients with mild to moderate myasthenia gravis in a National Referral Hospital in Indonesia
2021
eNeurologicalSci
23
100332
Neurology Department, Faculty of Medicine, Universitas Indonesia, Indonesia; Cipto Mangunkusomo National General Hospital, Jakarta, Indonesia
Octaviana, F., Neurology Department, Faculty of Medicine, Universitas Indonesia, Indonesia, Cipto Mangunkusomo National General Hospital, Jakarta, Indonesia; Yugo, H.P., Neurology Department, Faculty of Medicine, Universitas Indonesia, Indonesia, Cipto Mangunkusomo National General Hospital, Jakarta, Indonesia; Safri, A.Y., Neurology Department, Faculty of Medicine, Universitas Indonesia, Indonesia, Cipto Mangunkusomo National General Hospital, Jakarta, Indonesia; Indrawati, L.A., Neurology Department, Faculty of Medicine, Universitas Indonesia, Indonesia, Cipto Mangunkusomo National General Hospital, Jakarta, Indonesia; Wiratman, W., Neurology Department, Faculty of Medicine, Universitas Indonesia, Indonesia, Cipto Mangunkusomo National General Hospital, Jakarta, Indonesia; Ayuningtyas, T., Neurology Department, Faculty of Medicine, Universitas Indonesia, Indonesia, Cipto Mangunkusomo National General Hospital, Jakarta, Indonesia; Hakim, M., Neurology Department, Faculty of Medicine, Universitas Indonesia, Indonesia, Cipto Mangunkusomo National General Hospital, Jakarta, Indonesia
Background: During the COVID-19 pandemic, patients with myasthenia gravis (MG) are most likely to be affected by this situation. Corticosteroids and immunosuppressant agents increase the risk of severe infection. Furthermore, viral infection and some medications in COVID-19 may exacerbate MG symptoms. Case description: We presented three patients with MG who contracted COVID-19. All of the patients had a favourable outcome. Only one patient who was not treated with corticosteroids or immunosuppressant therapy experienced deterioration of MG symptoms, while the other patients who received immunosuppressant therapy did not develop MG exacerbation. Surprisingly, azithromycin did not provoke myasthenic crisis (MC) in patients with normal MGFA classification. Conclusion: Using immunosuppressant agents may not lead to MG deterioration and may not be related to unfavourable outcomes. © 2021 The Author(s)
COVID-19; Immunosuppressant; Myasthenia gravis
acetylcysteine; alanine aminotransferase; ascorbic acid; aspartate aminotransferase; azathioprine; azithromycin; C reactive protein; ceftriaxone; D dimer; hydroxychloroquine; methylprednisolone; mycophenolate mofetil; oxygen; paracetamol; procalcitonin; pyridostigmine; abduction; adult; anosmia; Article; blood analysis; body temperature; case report; clinical article; clinical classification; consultation; coronavirus disease 2019; coughing; deterioration; diarrhea; disease exacerbation; drug dose increase; dry cough; dysphagia; fatigue; female; fever; food intake; home quarantine; hospital admission; hospital discharge; hospitalization; human; human tissue; Indonesia; leukocytosis; lung auscultation; lung infiltrate; male; mastication; medical history; middle aged; mucus; muscle weakness;
Elsevier B.V.
24056502
Article
Q3
570
8868